DCM
SYRS

Delpha Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Delpha Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-42
Closed -$4K – 1282
2017
Q4 		$4K Buy
+42
New +$5.64K ﹤0.01% 1382

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Delpha Capital Management's SYRS Position: Q1 2018 in Review

Delpha Capital Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2018, closing a stake of 42 shares — an estimated $4K sold.

Delpha Capital Management first reported a position in SYRS in Q4 2017 and held it in 1 quarter. The position peaked at $4K in Q4 2017. 57 funds tracked by Wall St. Rank hold SYRS as of Q1 2018.

  • Delpha Capital Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 42 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2018, an estimated $4K.
  • Delpha Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $4K in Q4 2017.
  • 57 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.